Sana Biotechnology said it will suspend work on its allogeneic CAR‑T programs and trim its cell‑therapy pipeline, shifting resources amid broader challenges in allogeneic cell‑therapy development. The company’s move follows sectorwide reassessments of allogeneic strategies and aims to prioritize programs with clearer development paths or nearer‑term readouts. Sana’s decision reflects investor pressure and operational recalibration across cell‑therapy developers, and may affect partner collaborations, manufacturing plans and competitive dynamics in engineered‑cell therapeutics. The firm noted the change in an update covering multiple program adjustments.